What is the recommended dosing and titration protocol for intravenous immunoglobulin (IVIG), including initial dose, infusion rate adjustments, maintenance schedule, and modifications for impaired renal function?

IVIG Dosing and Titration Protocol

The standard IVIG dose is 2 g/kg divided over 2-5 days (typically 0.4 g/kg/day for 5 days), with initial infusion rates starting at 0.01 mL/kg/min (0.5 mg/kg/min) and gradually increasing to a maximum of 0.10 mL/kg/min (5 mg/kg/min) if tolerated. 1, 2

Initial Dosing by Indication

Severe Neurologic Conditions (Guillain-Barré, Myasthenia Gravis)

• Total dose: 2 g/kg IV divided over 5 days (0.4 g/kg/day) 1
• For Grade 3-4 immune-related adverse events from checkpoint inhibitors, this is the standard regimen
• May combine with plasmapheresis, though note that plasmapheresis immediately after IVIG will remove the immunoglobulin 1

Multisystem Inflammatory Syndrome in Children (MIS-C)

• Single dose: 2 g/kg based on ideal body weight 3
• In patients with cardiac dysfunction, may divide into 1 g/kg daily over 2 days 3
• Assess cardiac function and fluid status before administration 3

Cardiac Transplant Antibody-Mediated Rejection

• 2 g/kg divided over 2 consecutive days on days 1 and 2, then repeat on days 29 and 30 4
• Do not exceed 140 g total per course 4
• Re-dose monthly based on clinical response 4

Primary Immunodeficiency (Maintenance)

• 300-600 mg/kg every 3-4 weeks 2
• Adjust dose to achieve desired trough IgG levels and clinical response 2
• For measles exposure risk: increase to at least 530 mg/kg to maintain protective antibody levels 2

Immune Thrombocytopenia (ITP)

• First-line: 1 g/kg as single dose, may repeat if necessary 5
• Alternative: 0.4 g/kg daily for 2-5 consecutive days 6

Neonatal Hemolytic Disease

• 500 mg/kg over 4 hours 7
• Used as adjunct to phototherapy when bilirubin rises >8.5 micromol/L per hour 7

Maternal Hemolytic Disease of Fetus/Newborn

• 1 g/kg weekly starting before 13 weeks gestation 7
• Alternative regimen: 2 g/kg over 2 days, repeated every 3 weeks 7
• Continue until onset of fetal anemia requiring intrauterine transfusion 7

Infusion Rate Titration

Standard Protocol

1. Initial rate: 0.01 mL/kg/min (0.5 mg/kg/min) 2
2. Monitor for 30 minutes at initial rate 2
3. If tolerated, gradually increase to maximum 0.10 mL/kg/min (5 mg/kg/min) 2
4. Monitor vital signs throughout infusion 2

Managing Adverse Reactions During Infusion

• Slow or stop infusion if reactions occur 2
• If symptoms resolve promptly, resume at lower rate comfortable for patient 2
• For immediate reactions (headache, fever, chills, flushing): slow infusion, give symptomatic treatment with analgesics, antihistamines, or corticosteroids 8
• Consider premedication with hydrocortisone 100 mg IV or prednisolone 15 mg PO for patients with previous reactions 7

High-Risk Populations: Dose and Rate Modifications

Renal Impairment

• Administer at minimum dose and infusion rate practicable 2
• Ensure adequate hydration before administration 2
• Do not use in volume-depleted patients 2
• Monitor renal function (BUN, creatinine, urine output) before and during treatment 9
• Discontinue if renal function deteriorates 2
• Check IgA levels before initiation 9

Thrombosis Risk (Advanced Age, Immobility, Hypercoagulable States)

• Use minimum dose and slowest infusion rate 2
• Ensure adequate hydration 2
• Consider baseline blood viscosity assessment in hyperviscosity risk 2
• Monitor for signs/symptoms of thrombosis 2

First-Time or Restarted Therapy (>8 Weeks Gap)

• Proceed with extreme caution 6
• Higher risk of fever, chills, nausea, vomiting 2
• Risk of complement-mediated reactions in immunodeficient patients 6

Maintenance Dose Optimization

For chronic neurologic conditions requiring long-term therapy, individual dose titration can reduce maintenance doses by approximately 36-64% while preserving efficacy. 10

Titration Strategy

• Start with standard dose (typically 1 g/kg monthly) 10
• Gradually reduce to lowest effective dose based on clinical response 10
• Mean effective maintenance dose in chronic conditions: 0.6-0.7 g/kg monthly 10
• Range: 0.3-2.5 g/kg depending on individual response 10
• Treatment frequency typically cannot be extended - intervals remain fixed for each patient 11

Monitoring During Titration

• Use objective neurological examination and patient self-reports 10
• Dose reduction independent of weight, disease duration, or initial disability level 11
• Lower doses do NOT require shorter intervals between infusions 11

Critical Safety Monitoring

Before Each Infusion

• IgA level (before first dose) 9
• Renal function (creatinine, BUN) 9
• Cardiac function assessment if dysfunction present 3
• Hydration status 2

During Infusion

• Vital signs continuously 2
• Monitor for anaphylaxis, especially in IgA-deficient patients 9
• Watch for thromboembolic events 9

Post-Infusion Monitoring

• Renal function at regular intervals 9
• Blood viscosity in high-risk patients 2
• Hemolysis markers if high-dose or non-O blood group 2

Important Contraindications and Precautions

• Absolute contraindication: IgA deficiency with anti-IgA antibodies 2, 6
• Do not dilute with IV fluids 2
• Do not mix with other medications or IVIG formulations 2
• Do not use frozen or turbid solutions 2
• Discard partially used vials - no preservative present 2

Product-Specific Considerations

Different IVIG formulations vary in osmolarity, sodium content, IgA content, and stabilizers, affecting adverse reaction rates 12. Most common formulations include Privigen®, Gammagard®, and Gamunex®-C 12. Sucrose-containing products carry higher renal failure risk and should be avoided in high-risk patients 8.